Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy: A Handbook for Diagnosis and Management

ISBN-13: 9783030568238 / Angielski / Miękka / 2021 / 363 str.

Maria E. Suarez-Almazor; Leonard H. Calabrese

Spis treści

PART 1 - INTRODUCTION

1. Cancer Immunology and the evolution of immunotherapy 

2. Cancer immunotherapy: overview 

3. Pathogenesis of immune-related adverse events

PART 2 – IMMUNE-RELATED ADVERSE EVENTS WITH IMMUNE-CHECKPOINT INHIBITORS

4. Arthritis 

5. Polymyalgia rheumatica

6. Myositis

7. Sicca syndromes 

8. Sarcoidosis 

9. Miscellaneous rheumatic syndromes 

10. Non-rheumatic immune-related adverse events

11. Immune-related adverse events with other cancer

immunotherapies

PART 3 – CANCER IMMUNOTHERAPY IN PATIENTS WITH PRE-EXISTING RHEUMATIC DISEASES

12. Inflammatory arthritis

13. Other rheumatic autoimmune diseases

14. Choosing the right therapy

15. Risk-benefit considerations

16. Patient education and shared-decision making

O autorze

Maria E. Suarez-Almazor, MD, PhD. 

Barnts Family Professor

Departments of Health Services Research and General Internal Medicine, Section of Rheumatology and Clinical Immunology

The University of Texas MD Anderson Cancer Center

FCT 9.5026

1400 Pressler St (Unit 1444)

Houston, TX, 77030

msalmazor@mdanderson.org

Leonard H. Calabrese, D.O.

Professor of Medicine, 

Cleveland Clinic Lerner College of Medicine

RJ Fasenmyer Chair of Clinical Immunology

Vice Chairman, Department of Rheumatic and Immunologic Diseases

College of Medicine of Case Western Reserve University

9500 Euclid Avenue, Desk A50

Cleveland, Ohio 44195

CALABRL@ccf.org

Blurb

With the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. 

This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk–benefit ratios when managing patients with rheumatic irAE.

Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.